You are here


About TTC

The National Cancer Institute’s Technology Transfer Center (TTC) facilitates partnerships between the NIH research laboratories and external partners. With specialized teams, TTC guides the interactions of our partners from the point of discovery to patenting, from invention development to licensing. We play a key role in helping to accelerate development of cutting-edge research by connecting our partners to NIH’s world-class researchers, facilities, and knowledge.

Who We Are

Our team of technology transfer specialists has specialized training in invention reporting, patenting, patent strategy, executing technology transfer agreements and marketing. TTC is comprised of professionals with diverse legal, scientific, and business/marketing expertise. Most of our staff hold doctorate-level technical and/or legal training. 

How We Can Help

If you are:
  • A pharmaceutical or biotechnology company representative interested in solving a specific technical issue or developing your business and building strategic alliances, we invite you to search for Available Technologies and/or contact  us to locate available technologies; or

  • A university researcher interested finding a collaborator or research materials or a non-profit organization interested in finding treatment options for patients or to promote the development of NCI technologies into novel therapies; or

  • An NIH Investigator interested in patenting your discovery or in need of resources to develop your technology that are not available at NIH, NCI TTC can help you find companies to co-develop or license your technology.

We invite you to contact our Invention Development and Marketing Unit. We will help connect you to the right resources.  

Adding Value

Our partnerships have resulted in the commercialization of therapeutics, vaccines, diagnostics, medical devices and research tools that benefit patients worldwide. Technology  transfer metrics are another way to understand and quantify the work we do and the value we provide.

 4,529 CTA/MTA/CDAs signed, 156 Invention Reports, 146 New licenses, 71 issued patents, 319 active CRADAs, and 64 new CRADAs.
Wednesday, April 12, 2017